Synerx Pharma announces FDA submission of Isosulfan Blue injection ANDA



Closely related animal species share most of their genes and look almost identical. However, minor morphological differences allow us to tell them apart. What is the genetic basis for these differences? Often, the explanation is provided by minor changes in spatial and temporal activity of transcription factors - “regulator” genes which are conserved throughout the

Full Post: What are ‘orphan’ genes needed for?

Synerx Pharma, LLC has announced the submission to the FDA of Isosulfan Blue Injection (generic equivalent to Lymphazurin, Covidien (formerly US Surgical)).

This ANDA submission is the culmination of a four year joint effort by Synerx Pharma, LLC and its exclusive raw material supplier Apicore, LLC. According to Synerx Pharma and Apicore, the active ingredient is extremely difficult to synthesize. Synerx Pharma stated that this product fits nicely into their Company’s strategic direction; it is a difficult to produce product, serves a critical medical need, and represents an unmet market need.

Lymphazurin has been in limited supply for a number of years, with shortages due to supply and manufacturing problems in 2001, 2002, 2006, 2007, and 2008.

Synerx Pharma believes the ANDA submission, which it has already submitted, qualifies for the FDA Office of Generic Drug’s GIVE (Generic Initiative for Value and Efficiency) program. This program seeks to provide an accelerated FDA review of generic products.

Indications and Usage: Lymphazurin 1% (isosulfan blue) upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities.

http://www.synerxpharma.com

Link




Sun Pharmaceutical Industries Ltd. announced that together with its subsidiaries, it has received final approval from U.S. FDA for several Abbreviated New Drug Applications (ANDA). Approval was received for generic hydocodone bitartate with acetaminophen (APAP) tablets. Approval was also received for generic Aredia(R), pamidronate disodium for injection USP, generic Lopid (R), gemfibrozil tablets, USP, and

Full Post: Sun Pharmaceutical receives FDA approvals for 4 generics



Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil’s chronic pain treatment Duragesic. Shipment of this product has commenced.

Full Post: Teva granted FDA approval for Fentanyl transdermal system



Watson Pharmaceuticals, Inc. has announced that its subsidiary, Watson Laboratories, Inc., has received final approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets (XL) in the 150 mg strength. Bupropion Hydrochloride Extended-Release Tablets is the generic equivalent to GlaxoSmithKline’s Wellbutrin XL(R) product,

Full Post: Watson Pharmaceuticals receives FDA approval for generic Wellbutrin XL



Mylan Inc. has announced that its subsidiary, Mylan Pharmaceuticals Inc., received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 10 mg and 20 mg. Fluoxetine Capsules, indicated for the treatment of premenstrual dysphoric disorder (PMDD) are the generic version of Eli Lilly’s

Full Post: Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules



Mylan Inc. has confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Cephalon Inc., Eurand Inc. and Anesta AG in connection with the filing of an Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg, the generic version of AMRIX Capsules. Mylan

Full Post: Mylan confirms first-to-file patent challenge of AMRIX capsules